OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBluecross IdahoPolicy MP 7.01.25

Spinal Cord and Dorsal Root Ganglion Stimulation

Customize your policy alerts

Sign up for Bluecross Idaho Policy MP 7.01.25 alerts

Get alerted when Policy MP 7.01.25 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical policy governing use of spinal cord stimulation (SCS) and dorsal root ganglion stimulation (DRGS) for treatment of severe, chronic trunk or limb pain refractory to other therapies; applies to Blue Cross of Idaho benefit plans and affected providers/members.

Policy Summary

PayerBluecross Idaho

PolicySpinal Cord and Dorsal Root Ganglion Stimulation

Policy CodePolicy MP 7.01.25

Change TypeRoutine review — no material change

Effective DateApr 30, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionDocument a temporary stimulation trial and confirm ≥50% pain reduction before approving permanent implantation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

50%trial success threshold

3-7 daystrial duration

7 RCTsRCTs reviewed

17%-32%device complications (range)

8%explant rate (RELIEF)

Coverage Criteria for Spinal Cord and Dorsal Root Ganglion Stimulation

Medical necessity for SCS and DRGS

Covered when ALL of the following are met

Primary coverage criteria: Severe and chronic pain of the trunk or limbs that is refractory to all other pain therapies; procedure performed according to policy guidelines including multidisciplinary evaluation, documentation of prior conservative/interventional therapies attempted, and informed consent regarding device and procedural risks.N/A

Reflects policy statement and Medicare/NICE guidance on treatment‑refractory status and required evaluation.

Trial stimulation requirement: A stimulation trial (temporary epidural electrode) is performed prior to consideration of permanent implantation and is documented per device labeling and site protocol.Typical trial duration: 3-7 days; success commonly defined as >=50% reduction in pain symptoms

FDA and policy guidance recommend and expect a documented temporary trial prior to permanent implantation.

Policy Summary

PayerBluecross Idaho

PolicySpinal Cord and Dorsal Root Ganglion Stimulation

Policy CodePolicy MP 7.01.25

Change TypeRoutine review — no material change

Effective DateApr 30, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionDocument a temporary stimulation trial and confirm ≥50% pain reduction before approving permanent implantation.

SourceLink

On This Page

Responder requirement for permanent implantation: Permanent spinal cord stimulation or dorsal root ganglion neurostimulation is provided only after a successful trial defined by clinically meaningful pain reduction reported during the trial period.>=50% pain reduction during trial commonly used

Trials and policy use >=50% pain reduction during temporary trial as eligibility for permanent implant.

Prior conservative therapy requirement: Documented attempts and failure (or unsuitability/contraindication) of appropriate conventional medical management and other less‑invasive therapies prior to SCS/DRG consideration.NICE: >=6 months of persistent pain despite conventional management is a referenced standard; some trials required failure of >=2 drug classes

Consistent with Medicare conditions and trial inclusion criteria; required documentation should be included in the record.

Device/programming and pre‑implant documentation: Before implantation, provide patient education and device labeling, document device manufacturer/model/UDI, develop an individualized programming/treatment/follow‑up plan, and discuss MRI compatibility and risks/benefits of device options (standard, burst, high‑frequency, DRG).N/A

Policy guidelines specify pre‑implant counseling, patient education, and documented individualized plan.

Investigational / Not covered situations

The following are considered investigational (not covered)

Investigational indications: Spinal cord stimulation or dorsal root ganglion stimulation for treatment of critical limb ischemia to forestall amputation; refractory angina pectoris; heart failure; cancer‑related pain; and other indications not specified as medically necessary in this policy.N/A

Policy explicitly states SCS is investigational in these situations; systematic reviews found insufficient evidence for benefit in these indications.

Use without documented trial success: Permanent implantation performed without documentation of a successful temporary stimulation trial (or without meeting trial responder criteria) is considered investigational/not supported by the trial protocols and evidence base.Failure to document >=50% pain reduction during trial commonly leads to exclusion from implantation

Trials excluded patients who failed trial stimulation; policy expects documentation of trial and outcome.

Uses lacking RCT support or judged insufficient: Use of SCS/DRG for indications where randomized controlled trials and systematic reviews do not show sufficient improvement in net health outcome (e.g., routine use in chronic ischemic pain outside of research) is considered investigational.N/A

NICE and evidence summaries cited caution for ischemic indications and other conditions with insufficient evidence.

Initial SCS coverage

Covered when ALL of the following are met

Population indication: Patient has treatment‑refractory chronic pain of the trunk or limbs (examples: failed back surgery syndrome, complex regional pain syndrome, arachnoiditis, radiculopathies, phantom limb/stump pain, peripheral neuropathy, painful diabetic neuropathy).N/A

Trial and RCT populations define eligible indications for initial SCS consideration.

Prior therapies attempted: Documented attempts and inadequate response to appropriate conservative medical management and other indicated therapies (medical, rehabilitative, and when applicable, prior surgical options).Some trials required failure of >=2 drug classes or >=6 months of symptoms

Consistent with trial inclusion criteria and Medicare guidance regarding late‑resort use.

Temporary trial performed and documented: A temporary epidural lead trial is performed and documented according to device labeling/site protocol prior to permanent implantation.Typical trial duration: a few days to 1–2 weeks (commonly 3–7 days); successful trial commonly defined as >=50% pain reduction

RCTs universally used a trial period and FDA recommends temporary electrode trial before permanent implant.

Successful trial response: Patient demonstrates clinically meaningful improvement during the trial and meets trial responder criteria documented in the record to support proceeding to permanent implantation.>=50% reduction in pain during trial period commonly required

RCTs and policy cite >=50% pain reduction as the common responder threshold for proceeding to implantation.

Informed decision and documentation: Multidisciplinary screening (including psychosocial assessment where indicated), informed consent discussing risks (infection, lead migration, explantation rates, neurologic risks), and documentation of device details (manufacturer, model, UDI) and individualized follow‑up/programming plan are completed and recorded.N/A

Policy guidelines and Medicare/NICE recommendations emphasize multidisciplinary evaluation and documentation prior to implantation.

Implied criteria for permanent implantation

Coverage is supported where randomized trial evidence and trial stimulation demonstrate benefit and where risks/complications are documented

Appropriate indication and candidacy: Chronic intractable pain appropriate for neurostimulation (eg, neuropathic trunk/limb pain) with documentation that other therapies failed or were unsuitable.N/A

Reflects trial eligibility and registry populations informing implantation decisions.

Successful trial prior to permanent implant: A temporary stimulation trial was completed and the patient met the predefined success criteria (commonly >=50% pain reduction) prior to permanent implantation.>=50% trial pain reduction commonly used

RCTs reported permanent implantation only for trial responders; trials excluded trial failures from implantation.

Risk‑benefit discussion and consent: Provider discusses documented device and procedure risks (including device‑related complications, explantation rates, infection, lead migration) and patient accepts risks prior to permanent implantation.N/A

Registry data report device complications and explant rates that should be discussed and documented.

Burst SCS evidence

Burst SCS evidence and interpretation

Trial evidence summary: Randomized trials of burst stimulation versus tonic SCS or sham report reductions in pain scores; the SUNBURST trial showed noninferiority (and statistical superiority on mean VAS) and patient preference for burst, but many burst trials were small, short‑duration, or had methodological limitations.N/A

Systematic reviews rated evidence for burst SCS as low/very low for some small trials; SUNBURST provided the largest RCT evidence in SCS‑naive patients.

Clinical interpretation: Burst programming is an alternate mode of standard SCS and may be considered in selected patients based on trial results and patient preference; clinical decisions should weigh limited sample sizes and variable follow‑up in the evidence base.N/A

Policy describes burst as a programming option with heterogeneous evidence; registries inform long‑term complication rates.

Coverage context and implantation eligibility

Coverage considerations and clinical indications summarized from trials and section summaries

General coverage context: SCS (standard, burst, high‑frequency) and DRGS are treatment options for individuals with treatment‑refractory chronic trunk or limb pain when performed in populations similar to those studied in RCTs and systematic reviews.N/A

Section summaries conclude evidence is sufficient for treatment‑refractory neuropathic trunk/limb pain based on consistent trial results.

Permanent implantation eligibility: Permanent implantation should be limited to patients who demonstrate adequate response to a documented temporary trial (eg, >=50% pain relief) and where prior conservative therapies have been tried and documented as unsuccessful or unsuitable.>=50% pain relief during trial

Trials and policy summaries emphasize trial response as a gate to permanent implantation.

Trial-based eligibility and responder criteria

Clinical trial-based eligibility and outcome criteria reported in RCTs

Trial stimulation and responder requirement: Randomized trials required a temporary trial stimulation period and commonly required at least 50% pain relief during the trial to be eligible for permanent implantation.>=50% pain relief during trial

Examples: Petersen et al, Kapural et al, and ACCURATE used trial responder thresholds for implantation eligibility.

Prior conservative therapy in trial enrollment: Many RCTs enrolled patients who had failed conventional medical management or pharmacologic therapy; some trials required failure of >=2 drug classes or >=6 months of symptoms prior to enrollment.failed >=2 drug classes; >=6 months duration in some trials

These trial eligibility features inform expected prior therapy documentation for candidates.

Evidence evaluation criteria

Evidence and clinical context used to evaluate DRGS and high-frequency SCS

Evidence standards and interpretation: Preference is given to RCTs and prospective comparative trials for efficacy; evidence interpretation accounts for prior SCS exposure (trials enrolling SCS‑naive patients showed benefits for high‑frequency SCS, while crossover trials in previously treated patients had limitations such as period effects).N/A

Study selection criteria and trial designs guide evidence grading and applicability.

DRGS intervention and rationale: DRGS targets the dorsal root ganglion via an epidural approach to provide focal neuropathic pain control; ACCURATE RCT supports DRGS benefits in selected neuropathic lower‑limb pain populations.N/A

Clinical context notes DRGS as an alternative to standard SCS for neuropathic indications.

Outcome domains: Effectiveness assessment should include IMMPACT core outcome domains: pain intensity, physical functioning, emotional functioning, and participant ratings of overall improvement.N/A

Policy references IMMPACT recommended outcome domains to guide evidence evaluation.

Evidence-informed eligibility and response criteria

Findings from key RCT (ACCURATE) and systematic reviews that inform coverage decisions

ACCURATE trial enrollment criteria: Chronic (>=6 months), intractable neuropathic lower‑limb pain (CRPS or causalgia), failed >=2 drugs from different classes, and no previous neurostimulation; temporary trial lasting 3 to 30 days was used with >=50% VAS reduction required for permanent implantation eligibility.>=6 months; >=50% VAS reduction during trial; failed >=2 drug classes

ACCURATE provides a model for trial duration, responder threshold, and prior therapy requirements used in evidence‑informed eligibility.

DRGS clinical outcomes: DRGS showed higher rates of treatment success and noninferiority/superiority on selected pain and functional outcomes at 3 and 12 months compared with standard SCS in the ACCURATE RCT.3 and 12 month outcomes reported

DRGS demonstrated benefit in an unblinded RCT and systematic reviews summarized these findings.

Evidence summaries by indication

Evidence summaries and findings for select conditions where SCS has been studied

Critical limb ischemia: Pooled analyses of small RCTs suggest a possible reduction in amputations with SCS (absolute limb‑salvage difference ~11%), but results are inconsistent and evidence insufficient to determine net health outcome benefit for routine use.N/A

Cochrane and systematic reviews identified limited trials and heterogeneous results.

Refractory angina pectoris: Multiple small RCTs and systematic reviews show mixed results; larger, higher‑quality trials are needed and recent trials have not demonstrated consistent primary outcome benefit.N/A

Evidence is variable with some trials terminated early or underpowered; policy judges evidence insufficient.

Other conditions (heart failure, cancer‑related pain): Evidence for SCS in heart failure and cancer‑related pain is limited (small trials, observational data, or case series) and currently insufficient to determine net health outcome benefit.N/A

Policy sections summarize limited trial numbers and conclude insufficient evidence for routine coverage.

Coverage conclusions by indication

Coverage conclusions and sufficiency of evidence by indication

Treatment‑refractory chronic trunk or limb pain (standard SCS): Systematic reviews and RCTs show clinically and statistically significant pain reduction and medication reduction in selected neuropathic populations; evidence is sufficient to determine improvement in net health outcome when policy criteria are met.N/A

Supported indication per policy conclusions and section summaries.

High‑frequency SCS: RCTs enrolling SCS‑naive patients show clinically and statistically significant benefits for high‑frequency SCS compared with comparators; evidence is sufficient for selected populations not previously treated with SCS.N/A

Interpretation differs for patients previously treated with SCS where a crossover trial found no benefit and had methodological limitations.

Dorsal root ganglion (DRG) neurostimulation: Systematic reviews and an RCT demonstrate higher treatment success rates and noninferiority or superiority on selected outcomes versus standard SCS; evidence is sufficient for selected neuropathic lower‑limb pain populations.N/A

ACCURATE RCT findings support DRGS effectiveness at 3 and 12 months.

Critical limb ischemia: Pooled trial data show mixed results with insufficient evidence to determine improvement in net health outcome for routine SCS use in critical limb ischemia.N/A

Policy concludes evidence insufficient for routine coverage.

Treatment‑refractory angina pectoris: Multiple small RCTs with mixed results and two recent RCTs without significant primary outcome benefit; evidence insufficient to determine net health outcome benefit.N/A

Policy classifies this indication as lacking sufficient evidence.

Heart failure: A small body of studies (including 2 RCTs) with heterogeneous outcomes; evidence insufficient to establish benefit and further research needed.N/A

Policy summarizes a 2024 systematic review finding mixed results.

Cancer‑related pain: No randomized trials identified and only case series available; evidence insufficient to determine net health outcome benefit for SCS in cancer‑related pain.N/A

Policy states lack of RCT evidence for cancer‑related pain.

General coverage criteria for SCS/DRG

Coverage considerations reflected from cited guidance and Medicare policy:

Core requirements for SCS/DRG consideration: Multidisciplinary screening and evaluation (including psychological assessment where indicated), documentation that other treatment modalities have been tried and found unsatisfactory or are contraindicated, and availability of the facility and personnel for diagnosis, training, and follow‑up.N/A

Derived from Medicare and society guidance (NICE, ASRA‑PM) emphasizing team evaluation and psychosocial screening.

Temporary trial precedent to implantation: Demonstration of pain relief with a temporarily implanted electrode must precede permanent implantation except where guidance allows an exception (eg, anginal pain per some guidelines); the trial and its outcome must be documented.>=50 mm VAS (NICE candidate criteria) and >=6 months duration referenced for neuropathic pain; trial success commonly >=50% pain reduction

NICE specifies pain severity/duration thresholds and recommends specialist team assessment; Medicare requires demonstration of pain relief with a temporary electrode.

Documentation and coding requirements: Prior authorization should confirm diagnosis, prior treatment attempts, documented trial stimulation and response, device details (manufacturer, model, UDI), and that appropriate CPT/HCPCS/ICD‑10‑PCS codes correspond to the performed procedure; inclusion of codes does not guarantee coverage.N/A

Policy and prior authorization modules reference required documentation and coding concordance for authorization decisions.

Coverage: SCS (standard or high-frequency) and DRGS are considered medically necessary for treatment of severe, chronic trunk or limb pain that is refractory to other therapies when performed according to policy guidelines. The policy explicitly states SCS is investigational for other indications, including but not limited to treatment of critical limb ischemia to forestall amputation, refractory angina pectoris, heart failure, and cancer-related pain.

Evidence context: randomized controlled trials and systematic reviews support benefit of SCS and DRGS in selected refractory neuropathic pain populations (examples: failed back surgery syndrome, complex regional pain syndrome, diabetic neuropathy), with consistent reductions in pain at 6 months in RCTs. Trial designs typically required a temporary stimulation trial and documented trial response prior to permanent implantation.

Continuation/implantation criterion: RCTs and key trials required a documented temporary trial of stimulation before permanent implantation. The common effectiveness threshold used in trials was ≥50% pain reduction during the trial period; patients who did not demonstrate improvement during the trial were not continued on SCS and were treated as nonresponders in analyses.

Documentation expectation: the policy and trial protocols indicate that permanent implantation should only be performed after a successful trial period is recorded in the medical record (trial duration and measured pain reduction per trial protocol).

Complication context: registries and retrospective series report substantial device- and procedure-related adverse events. In the RELIEF registry (N=1289) an explant rate of 8% (annualized ~3.5%/yr) was reported and device- and procedure-related serious adverse events (infections, neurological deficits, device failures) were documented. Older series reported hardware complications such as lead migration (≈23%) and infection requiring removal. These complication and explant rates should be discussed with patients during informed consent and considered in clinical decision-making.

Applicable population: the policy applies to individuals with treatment-refractory chronic trunk or limb pain — i.e., chronic pain that has failed appropriate conventional medical or surgical therapies. Examples cited include failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), arachnoiditis, radiculopathies, phantom limb/stump pain, peripheral neuropathy, and painful diabetic neuropathy. Prior conservative treatments and documentation of failure are expected as part of candidate selection.

Example trial enrollment exclusions: Kapural et al (2022) enrolled individuals with nonsurgical refractory back pain and specifically excluded patients with a history of spine surgery and those considered acceptable candidates for spine surgery. Trial participants received a trial stimulation period (up to 14 days in that study) prior to permanent implantation.

Crossover RCT limitations: some trials using crossover or small randomized designs have methodological limitations that affect interpretation. For example, a crossover RCT of high-frequency SCS in patients previously treated with SCS found no difference versus sham, but the result was limited by a significant period effect. Other burst-stimulation crossover trials were small with short follow-up and downgraded in quality assessments; these limitations should temper extrapolation of results to all populations.

Trial non-responders excluded from implantation: in trials such as ACCURATE and others, patients who failed to achieve the trial success threshold (commonly defined as ≥50% reduction in pain) during the temporary stimulation period were excluded from permanent implantation and considered treatment failures for intent-to-treat analyses.

Coverage exclusions: the policy excerpt does not list additional explicit procedural or diagnostic exclusions beyond stating that SCS is investigational for the conditions listed; inclusion of procedural codes in the policy does not by itself guarantee coverage — member-specific benefit terms and documentation of medical necessity apply.

Cancer-related pain: no randomized controlled trials were identified for SCS in patients with cancer-related pain; available evidence is limited to case series. Therefore the role of SCS for refractory cancer-related pain is unestablished in this policy excerpt.

NICE recommendation on ischemic-origin pain: NICE recommends SCS as an option for adults with chronic neuropathic-origin pain meeting severity and duration criteria and a successful trial, but does not recommend SCS for chronic pain of ischemic origin except in the context of research.

Coding note: listing procedure, device, or diagnosis codes in the policy is for reference only and does not guarantee coverage. Coverage determinations remain subject to the member-specific benefit plan and medical policy requirements.

ICD-10-PCS coding: the policy notes that ICD-10-PCS procedure codes are used only for inpatient services; outpatient claims should use the appropriate CPT/HCPCS codes as listed in the coding section.

Use outside defined indications: use of spinal cord stimulation for conditions not defined as medically necessary in the policy (see investigational list) — for example refractory angina, critical limb ischemia outside research settings, heart failure, or cancer-related pain — is considered investigational or not medically necessary based on the evidence summaries in this document.

Routine use for critical limb ischemia is not supported by consistent evidence; pooled analyses suggest a possible limb-salvage benefit in some small trials but overall evidence is insufficient to determine improved net health outcome.

Permanent implantation without trial or conservative care: trial protocols and this policy consistently require documentation of a successful temporary stimulation trial before permanent implantation. Permanent implantation without documentation of a successful trial or without prior appropriate conservative/surgical management is not supported by the trial evidence and is inconsistent with the policy's described pathways.

Burst SCS evidence limitations: systematic reviews and the small crossover RCTs of burst stimulation were often limited by very small sample sizes, short follow-up, and flaws in analyses; evidence strength for burst SCS may be rated low or very low in some reviews, limiting confidence in long-term comparative effectiveness.

Summary statement: overall evidence supports SCS and DRGS as reasonable treatment options for selected patients with treatment-refractory chronic trunk or limb pain when performed in accordance with trial-based pathways (including a documented successful trial) and with informed discussion of risks/complications. The policy therefore covers these interventions with specific criteria and documents investigational status for other indications where evidence is insufficient.

Insufficient evidence for CLI and related indications: for critical limb ischemia the pooled trial results are heterogeneous and inconsistent; for refractory angina, heart failure, and cancer-related pain, RCTs are small, mixed, or absent, and the evidence is insufficient to support routine SCS for these indications.

Indications with insufficient evidence: the policy lists refractory angina pectoris, critical limb ischemia (outside research), heart failure, and cancer-related pain among conditions where evidence is insufficient or inconsistent; such uses are considered investigational or not medically necessary depending on the indication and payer criteria.

Required Prior Treatments and Refractory Criteria

Refractory to other pain therapies

Candidate must be refractory to other therapies and prior attempts documented

Refractory to other pain therapies: Patient has failed appropriate conservative, pharmacologic, and where applicable, surgical therapies prior to consideration of SCS/DRGS; documentation should describe prior modalities tried and response.N/A

Trials and Medicare guidance require prior unsuccessful therapies; ACCURATE required failure of ≥2 drug classes and chronicity ≥6 months in selected trials

Examples of prior therapies to document: Examples include conventional medical management (pharmacologic therapy, physical therapy), interventional procedures, and reoperation when applicable.

Specific enumerated prior therapies vary by trial and clinical context

Document prior trials of appropriate medical and/or surgical therapy before SCS consideration

Document prior trials of appropriate medical and/or surgical therapy before SCS consideration.

Required prior-treatment documentation: Provide documentation of prior conservative and interventional therapies attempted and found unsatisfactory (eg, pharmacologic regimens, physical therapy, interventional blocks, reoperation where applicable), including duration and outcomes of those treatments.N/A

Randomized trials generally required failure of conventional medical management before enrollment

Documentation of prior conservative therapy attempts expected (exact requirements not specified here)

Expected documentation elements: Record baseline pain intensity and duration, prior therapies and duration, rationale for SCS/DRGS candidacy, informed consent discussions (including MRI compatibility), and provision of manufacturer's device labeling and individualized programming/follow-up plan.N/A

Policy guidelines and trial reports emphasize these documentation items

Prior conventional medical management or surgical therapy attempted (implied by 'treatment-refractory' and comparators listed)

Implied comparator-based requirement: Evidence and trial comparators imply SCS/DRGS should be considered after standard SCS, medical therapy, or surgical therapy have been attempted and found inadequate for the patient.N/A

Comparators in trials include CMM, reoperation, and physical therapy

Failure of conservative/CMM therapy prior to trial enrollment as described in RCTs

Trial-based conservative-failure requirements: RCTs enrolling patients for SCS/DRGS generally required prior failure of conventional medical management or pharmacologic treatments; some trials (eg, ACCURATE) specified failure of ≥2 drug classes and chronicity ≥6 months.failed >=2 drug classes where specified; >=6 months chronicity in some trials

Exact prior-therapy requirements vary by trial; use trial criteria as guidance for documentation

Comparators include standard SCS, medical therapy, or surgical therapy — implies consideration of existing therapies prior to DRGS/SCS selection

Comparators indicating prior therapies: Document that standard medical therapy, revascularization (where relevant), or surgical options were considered or attempted as appropriate to the condition before selecting SCS/DRGS.

Context-specific (eg, angina, critical limb ischemia) comparators guide expected prior treatments

failed >=2 drug classes

Example requirement from ACCURATE and other trials

Failed >=2 drug classes (example trial requirement): Some trials (eg, ACCURATE) required documented failure of two or more drug classes prior to enrollment; when applicable, document prior medication classes tried and response.failed >=2 drug classes

Use trial criteria to inform documentation but recognize payer-specific requirements may differ

Prior standard medical therapy or revascularization is common comparator — SCS considered after refractory response

Condition-specific prior therapy examples: For conditions such as refractory angina or critical limb ischemia, document whether revascularization or standard therapies were attempted or were unsuitable before considering SCS/DRGS.

Trials and guidelines use these comparators to define prior care pathways

Prior conservative treatments should have been attempted and documented before SCS is considered

Documentation expectation: Providers should document prior conservative and interventional therapies attempted, multidisciplinary screening including psychological assessment, and rationale for SCS/DRGS candidacy consistent with guidance (eg, NICE, Medicare, society consensus).N/A

NICE specifies ≥6 months duration and ≥50 mm VAS in candidate criteria as an example

Document attempts and failures of prior therapies before considering SCS/DRG (NICE: >=6 months persistent pain despite management)

Document attempts and failures of prior therapies before considering SCS/DRG (NICE example)

NICE candidate example: Where applicable, document pain severity and duration (eg, NICE criteria: pain ≥50 mm on a 0–100 mm VAS and duration ≥6 months despite appropriate conventional management) and that a specialist team assessed the patient and a successful trial was conducted.>=50 mm VAS; >=6 months duration

This is an example standard from NICE to inform documentation expectations

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Require and pass a stimulation trial before permanent implant

Conduct a stimulation trial per device labeling and only proceed to permanent implantation in patients who have undergone and passed the trial; providers typically perform a trial lasting 3–7 days with success usually defined as a 50% reduction in pain symptoms.

Trial should follow device labeling and FDA recommendations.
Permanent SCS should only be implanted after a passed stimulation trial.

Documentation Required

Document FDA‑recommended temporary epidural lead trial

Document the temporary epidural electrode trial and its outcome; the FDA recommends a trial period with temporary epidural lead prior to permanent implantation and prior authorization should require documentation of the trial and its result.

Record trial start/end dates, lead type (temporary epidural electrode), and patient-reported pain outcomes.
Include documentation of counseling and device labeling provided before trial.

Prior Authorization

Require trial documentation linking trial success to permanent implant

Prior authorization should require documentation of a successful temporary stimulation trial and prior conservative management attempts, consistent with randomized trial pathways where patients underwent a trial and received permanent implant only after reporting ≥50% pain reduction.

Submit evidence of prior conservative therapies attempted.
Provide trial outcome showing responder status (see trial threshold).

Prior Authorization

Permanent implantation requires ≥50% pain relief during trial

Ensure trial responders meet the trial success threshold used in trials: eligibility for permanent implantation required achieving at least 50% pain relief during the trial stimulation period.

Use patient-reported pain reduction (e.g., VAS/NRS) to document ≥50% improvement during trial.

Note

Adhere to RCT trial‑to‑permanent implant pathway (≥50% trial relief)

Follow trial‑to‑implant pathways used in randomized trials: perform a temporary trial period and proceed to permanent implantation only for patients achieving ≥50% pain relief during the trial.

Include trial duration and objective pain outcome in the authorization package.
Patients failing the trial should not proceed to permanent implantation.

Prior Authorization

Identify DRGS as epidural dorsal root ganglion stimulation in authorization

For DRGS prior authorization, note that DRGS targets the dorsal root ganglion using an epidural approach and is intended for individuals with treatment‑refractory chronic trunk or limb pain as an alternative to standard SCS or other therapies.

Indicate DRG target and epidural approach in the request.
Document rationale why DRGS is selected over standard SCS or other therapies.

Prior Authorization

Require temporary trial (3–30 days) with documented response before implant

A temporary stimulation trial is required prior to permanent implantation; trials in studies lasted typically 3 to 30 days and require documentation of response (e.g., ≥50% pain reduction) to proceed to permanent device.

Specify trial duration used at site (3–30 days) and recorded pain reduction.
Document absence of stimulation‑related neurologic deficits per trial protocols.

Documentation Required

Recommend temporary epidural electrode trial and document response

Recommend a temporary epidural electrode trial prior to permanent implantation and document the patient's response; FDA guidance and trial protocols describe temporary epidural lead placement before implant.

Provide device component details (lead, extension, power source) and stimulation parameters in documentation.
Record informed consent and counseling provided prior to trial.

Prior Authorization

Confirm treatment‑refractory diagnosis and prior failed therapies for SCS authorization

Prior authorization must confirm the diagnosis is treatment‑refractory chronic trunk or limb pain with documentation of prior failed medical and/or interventional therapies, since evidence supports neurostimulation primarily in these populations.

Include prior treatment history and reasons therapies were inadequate or contraindicated.
Align indication with trial populations (e.g., FBSS, CRPS, neuropathic pain).

Prior Authorization

Require SCS trial and multidisciplinary screening before implant

Prior authorization should confirm that a spinal cord stimulation trial was performed before permanent implantation and that multidisciplinary evaluation including psychosocial screening occurred, except where guidance allows an exception (e.g., anginal pain).

Include multidisciplinary screening results and psychological assessment findings.
If exception claimed (e.g., angina), provide supporting rationale and guidance citation.

Billing Rule

Provide CPT/HCPCS/ICD code list for prior authorization but verify benefits

Use the provided CPT/HCPCS and ICD‑10‑PCS codes as reference when submitting prior authorization requests; inclusion of codes in the policy does not guarantee coverage and determinations remain subject to member‑specific benefits.

List applicable procedure and supply codes in the authorization submission.
Verify member benefit terms even if codes appear in the policy.

Billing Rule

Use listed procedure/device codes for authorization and billing

When requesting authorization or submitting claims, use the procedure and device codes listed (CPT/HCPCS and ICD‑10‑PCS) that correspond to neurostimulator implantation, revision/removal, and programming services.

Include the specific ICD‑10‑PCS code that matches body part, approach, number of arrays, and rechargeable status.
Use CPT/HCPCS codes for implantation, revision, removal, and programming as listed.

Billing Rule

Reference lead/generator insertion and revision procedure codes in auth requests

For prior authorization of insertion or revision procedures, reference the procedure codes that correspond to spinal/neurostimulator lead and generator insertion or revision and ensure documentation supports the selected code.

Provide surgical details (approach, body part, number of arrays) to support the ICD‑10‑PCS code chosen.
Attach operative report or planned procedure note with authorization.

Billing Rule

Reference listed ICD‑10‑PCS codes for neurostimulator surgical procedures

When using ICD‑10‑PCS codes for neurostimulator procedures, reference the listed ICD‑10‑PCS codes for surgical insertion and revision of neurostimulator leads and generators and ensure the claim reflects the exact procedure descriptors.

Match the ICD‑10‑PCS code to the documented approach, body part, number of arrays, and rechargeable status.
Remember ICD‑10‑PCS codes are for inpatient services only where applicable.

Prior Authorization

Require prior authorization for listed implantation ICD‑10‑PCS codes

Prior authorization is required for spinal cord stimulator generator insertion and related device procedures coded with the listed ICD‑10‑PCS codes; authorizations must reflect the specific code for body part, approach, number of arrays, and rechargeable status.

Specify the exact ICD‑10‑PCS code and supporting operative/procedure documentation in the prior authorization.
Confirm inpatient versus outpatient coding conventions (ICD‑10‑PCS for inpatient).

Denial Risk

Avoid authorization for investigational indications (risk of denial)

Do not submit SCS/DRGS for indications considered investigational (e.g., critical limb ischemia to forestall amputation, refractory angina, heart failure, cancer‑related pain) because procedures performed for these investigational indications risk denial.

If submitting for these indications, include justification and reference to clinical trial or research context; expect likely denial.
Verify alternative coverage pathways for research settings if applicable.

Step Therapy

Verify failure of conservative treatments before SCS/DRGS

Confirm the patient has tried and failed appropriate conservative medical or surgical therapies before SCS/DRGS consideration; candidate selection requires confirming refractoriness to other pain therapies.

Document prior conservative treatments attempted and outcomes.
Include duration and reasons therapies were inadequate or contraindicated.

Documentation Required

Document prior medical or surgical therapy attempts

Document that the patient attempted appropriate medical or surgical therapies (conventional medical management or reoperation where relevant) prior to SCS consideration, consistent with trial comparators.

Provide records of pharmacologic trials, physical therapy, injections, or reoperations as applicable.
Note any contraindications to further conservative therapies.

Note

Consider RCT comparator context (burst vs standard SCS) when authorizing

Recognize that multiple RCTs compare burst SCS with conventional SCS or conventional medical management and that trial designs required trial stimulation prior to implantation; consider trial evidence when selecting therapy.

When proposing burst stimulation, reference relevant RCT pathway and trial success documentation.
Include rationale if selecting burst vs standard SCS based on trial evidence.

Step Therapy

Require prior conservative therapy before high‑frequency SCS

High‑frequency SCS is considered for individuals with treatment‑refractory chronic trunk or limb pain after conventional medical or surgical therapies have been tried; prior conservative management attempts should be documented.

If requesting high‑frequency SCS, provide documentation of prior conventional therapies and why HFSCS is indicated.
Align patient characteristics with trial populations when possible (e.g., SCS‑naive in some RCTs).

Step Therapy

Confirm failure of conventional medical management before trial

Verify that subjects have failed conventional medical management prior to trial enrollment—several trials required failure of conservative management before undergoing SCS trial.

Provide documentation of failed CMM or pharmacologic therapy attempts as described in trials.
For DRGS consideration, include failed medication trials (e.g., ≥2 drug classes when applicable).

Note

Treat SCS/DRGS as step‑therapy after listed comparators

Consider comparators used in trials (standard SCS, medical therapy, surgical therapy) as implying stepwise escalation of care; document prior conservative or alternative therapies before advanced neurostimulation.

List prior comparator therapies and outcomes to support that SCS/DRGS is a next‑step intervention.
Include justification for choosing neurostimulation over repeat/revision interventions if applicable.

Documentation Required

Document chronicity and failed ≥2 drug classes when applicable (ACCURATE precedent)

The ACCURATE trial required prior conservative therapy (chronic ≥6 months and failed ≥2 drug classes) before enrollment; when relevant, document medication class failures and chronicity to support authorization.

Document duration of pain (e.g., ≥6 months) and failure of ≥2 drug classes when claiming similarity to ACCURATE enrollment.
Attach medication trial records and responses.

Step Therapy

Require documentation of stepwise failure of conservative therapies

Stepwise failure of conventional therapies is implied in the evidence base for 'treatment‑refractory' pain; policy reviewers should verify that less invasive treatments and appropriate conventional management were attempted and found unsatisfactory before SCS/DRG.

Provide evidence of stepwise escalation and rationale for advancing to neurostimulation.
Include notes from multidisciplinary evaluation supporting candidacy.

Note

Documentation Required

Provide pre‑implant counseling, device details, and individualized plan

Provide pre‑implant counseling and patient education materials including manufacturer labeling, device manufacturer, model, and unique device identifier, and develop an individualized programming, treatment, and follow‑up plan; document informed consent.

Give patients manufacturer patient labeling and device information prior to implantation.
Document MRI compatibility discussion and individualized follow‑up plan.

Documentation Required

Document diagnosis, trial results, and prior therapies for authorization

Include in documentation the diagnosis of treatment‑refractory chronic trunk or limb pain, record of the temporary SCS trial and detailed trial outcomes (patient‑reported pain improvement), and prior therapies tried and failed.

Attach trial pain scores (baseline and trial), trial duration, and responder status.
List prior conservative and interventional therapies and dates.

Documentation Required

Provide clinical documentation: pain duration, prior therapies, trial results, device details

Submit required clinical documentation that mirrors registry and study reports: include duration of chronic pain, prior therapies failed, trial stimulation results (e.g., ≥50% pain reduction during trial), and device details including components and parameters.

Provide device component details (lead type, extension, power source) and stimulation parameters.
Include registry or long‑term outcome data if relevant to support medical necessity.

Documentation Required

Record baseline pain and objective trial outcomes (≥50% trial relief)

Document baseline pain intensity and prior treatments and include objective trial stimulation results (e.g., ≥50% pain relief during trial period) to support eligibility for permanent implantation.

Record baseline and trial VAS/NRS scores and functional outcome measures.
Include follow‑up pain scores where available.

Documentation Required

Document trial response: use ≥50% pain relief threshold

Trials required at least 50% pain relief during the trial stimulation to be eligible for permanent implantation; document trial response accordingly (responder commonly defined as ≥50% reduction in pain).

Use consistent responder definition (≥50% pain reduction) when reporting trial success.
If different thresholds used, provide justification and supporting evidence.

Documentation Required

Include IMMPACT core outcome domains in clinical documentation

Address IMMPACT core outcome domains in documentation when relevant: pain intensity, physical functioning, emotional functioning, and participant ratings of overall improvement, consistent with evidence standards.

Include measures of function and quality of life in addition to pain scores.
Report adverse events and device‑related complications.

Documentation Required

Document trial duration, VAS reduction (≥50%), and neurologic status

Document temporary trial details and objective reporting of pain reduction (e.g., ≥50% reduction in VAS as used in ACCURATE) and absence of stimulation‑related neurologic deficits for eligibility for permanent implantation.

Record trial duration (3–30 days), VAS change, and any neurologic findings.
If permanent implant planned, provide documentation that trial criteria were met.

Documentation Required

Document trial period outcomes and device components/parameters

Document trial stimulation period outcomes, device components (lead, extension, power source), and stimulation parameters (typical frequencies 100–1000 Hz) when reporting the intervention in authorization or claims.

Include stimulation mode (standard, burst, high‑frequency) and parameter settings.
Attach operative or procedure notes describing device components used during trial.

Documentation Required

Document prior treatments, multidisciplinary screening, and trial success

Providers must document prior conservative and interventional therapies attempted and unsatisfactory responses, multidisciplinary screening and evaluation (including psychological assessment), and results of a successful temporary stimulation trial when requesting authorization.

Attach multidisciplinary evaluation notes and psychological screening results.
List all prior interventions with dates and outcomes.

Billing Rule

Support ICD‑10‑PCS code selection with specific procedure details

Document supporting procedural details to justify the specific ICD‑10‑PCS code selected, including body part, surgical approach, number of arrays, and whether the device is rechargeable, because coding‑concordance issues may trigger claim denial.

Provide operative report describing approach and device characteristics.
Ensure inpatient use of ICD‑10‑PCS codes is appropriate (these codes are for inpatient services).

Note

Denial Risk

Investigational indications (expect denials for listed conditions)

Do not expect coverage for procedures performed for investigational indications (e.g., critical limb ischemia to forestall amputation, refractory angina, heart failure, cancer‑related pain); such requests risk denial.

If recommending SCS for these indications, document participation in approved research or provide strong justification; otherwise anticipate denial.
Refer to policy investigational list before submitting authorization.

Denial Risk

Risk of denial if FDA‑recommended trial period not documented

Verify and document that an FDA‑recommended trial period with temporary epidural lead was performed and recorded; lack of documentation of the recommended trial period may trigger denials.

Include trial lead implantation note and trial outcome in the authorization file.
If trial was not performed, provide justification for exception and supporting guidance.

Documentation Required

Document and counsel on device‑related risks and complication history

Document device‑related complications and counselling regarding risks (e.g., explantation, lead migration, infection, need for re‑intervention); high complication rates reported in registries should be discussed and supported in the clinical record.

Include discussion of explantation and hardware complication rates in informed consent.
Report any prior device complications when applicable.

Note

Ensure documentation supports distinct indication and applicability of evidence

Studies excluded duplicative or overlapping populations, implying that documentation should support distinct patient indication and applicability of cited evidence; ensure patient case aligns with evidence cited.

Provide indication‑specific evidence or rationale linking patient to trial populations.
Avoid relying on studies with overlapping cohorts without justification.

Note

Denial Risk

Do not proceed to permanent implant after failed trial (trial failure = non‑implantation)

Patients who fail the temporary stimulation trial are considered treatment failures and would not proceed to permanent implantation; document failed trial results and do not authorize permanent implant without trial success.

If trial failed, document alternative care plan and reason permanent implantation is not appropriate.
Include trial failure in the clinical record for audit and appeals.

Documentation Required

Document device‑related adverse events and their management

Report device‑related adverse events in documentation (e.g., changes in stimulation requiring intervention, battery end‑of‑life, infections requiring device removal) because these events have been observed in studies and may affect authorization decisions.

Include prior device adverse events in authorization/appeal documentation if relevant.
Detail any management or revisions performed for device complications.

Denial Risk

Triggers for denial: missing documentation of prior therapies, multidisciplinary screening, or trial success

Failure to document that other treatment modalities were tried and unsuccessful, lack of multidisciplinary screening including psychological assessment, or absence of demonstration of pain relief with a temporary trial electrode could trigger denial under Medicare‑like conditions.

Provide multidisciplinary team evaluation notes and psychological screening results.
Attach evidence of tried and failed modalities before implant consideration.

Billing Rule

Code inclusion does not guarantee coverage — verify member benefits

Inclusion of a code in the policy does not guarantee member coverage; benefit determinations remain subject to member‑specific plan terms and the medical policy.

Verify member benefits and coverage rules even when procedure codes are provided in the policy.
Document any member‑specific coverage determinations used to support authorization.

Billing Rule

Use ICD‑10‑PCS codes only for inpatient services (verify service setting)

ICD‑10‑PCS codes are only used for inpatient services; ensure inpatient status and correct use of ICD‑10‑PCS when these codes are submitted, as incorrect inpatient/outpatient coding may lead to denial.

Confirm service setting and choose ICD‑10‑PCS only for inpatient reporting.
Provide supporting inpatient documentation if ICD‑10‑PCS codes are used.

Denial Risk

Risk of denial for incorrect ICD‑10‑PCS mapping — ensure coding concordance

Claims may be denied if billed with incorrect ICD‑10‑PCS codes that do not match the described surgical approach, body part, number of arrays, or rechargeable status for stimulator generator insertion; ensure coding concordance with operative documentation.

Cross‑check operative note against chosen ICD‑10‑PCS code sequence before submission.
Correct miscoding of approach/body part/arrays to avoid claim denials.

Note

Coding: CPT, HCPCS, ICD-10-CM, and ICD-10-PCS References

FDA product codes referencedmixed

LGW	Stimulator, spinal-cord, totally implanted for pain relief (FDA product code) listed in regulatory status
PMP	Dorsal Root Ganglion Stimulator for Pain Relief (FDA product code) listed in regulatory status
GZB	Stimulator, Spinal-Cord, Implanted [Pain Relief] (FDA product code) listed in regulatory status

Covered CPT Codes (representative list)CPT

63650	Percutaneous implantation of neurostimulator electrode array; epidural
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural
63661	Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed
63662	Removal of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed
63663	Laminotomy or laminectomy, including fluoroscopy, when performed Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array

Programming and analysis CPT/HCPCSmixed

95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter, without programming
95971	Electronic analysis of implanted neurostimulator pulse generator/transmitter, without programming (variation)
95972	Electronic analysis with simple programming of implanted neurostimulator pulse generator/transmitter
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator
0788T	Electronic analysis with simple programming of implanted integrated neurostimulation system
0789T	Electronic analysis with complex programming of implanted integrated neurostimulation system (spinal cord or sacral nerve, 4 or more parameters)

HCPCS/Device supply codesHCPCS

C1778	Generator, neurostimulator (implantable) / Lead, neurostimulator (implantable) (listed in series)
C1787	Patient programmer, neurostimulator
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system (non-high frequency)
C1822	Generator, neurostimulator (implantable), with rechargeable battery and charging system (to be used for non-high frequency generators)
C1826	Generator, neurostimulator (implantable), high frequency, with rechargeable
C1883	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system
C1897	Adaptor/extension, pacing lead or neurostimulator lead (implantable)
L8679	Implantable neurostimulator pulse generator, any type
L8680	Implantable neurostimulator electrode, each
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension

1–10 of 13

1/2

Representative ICD-10-CM diagnosis codesICD-10

G56.40-G56.43	Causalgia of upper limb code range (representative diagnosis codes listed)
G57.70-G57.73	Causalgia of lower limb code range (representative diagnosis codes listed)
G89.21-G89.29	Chronic pain diagnosis code range
G89.4	Chronic pain, not elsewhere classified

Neurostimulator device and programming CPT/HCPCSmixed

L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension
0785T	Electronic analysis with simple programming of implanted integrated neurostimulation system (spinal cord or sacral nerve), 1-3 parameters (listed in context)
0788T	Electronic analysis with complex programming of implanted integrated neurostimulation system (spinal cord or sacral nerve), 4 or more parameters (listed in context)
0789T	Referenced alongside 0788T/0785T in programming/revision context

Representative ICD-10-CM diagnosis code ranges for severe and chronic painICD-10

G56.40-G56.43	Causalgia of upper limb code range (representative list inclusion)
G57.70-G57.73	Causalgia of lower limb code range (representative list inclusion)
G89.21-G89.29	Chronic pain codes (representative list inclusion)
G89.4	Chronic pain, not elsewhere classified / chronic pain syndrome
G90.50-G90.59	Autonomic/other neuropathic pain codes (included with chronic pain syndrome)
M25.50-M25.579	Pain in joint range
M54.10-M54.18	Pain in thoracic spine range
M54.30-M54.32	Radiculopathy code range
M54.40-M54.42	Sciatica code range
M54.5	Lumbago with sciatica

1–10 of 17

1/2

ICD-10-PCS procedure codes for implantation, removal, revision of neurostimulator leads and generatorsICD-10

00HU0MZ	Surgical, central nervous system, insertion, spinal canal, neurostimulator lead, code by approach (ICD-10-PCS)
00HU3MZ	Surgical, CNS, insertion, spinal canal, neurostimulator lead (ICD-10-PCS)
00HU4MZ	Surgical, CNS, insertion, spinal canal, neurostimulator lead (ICD-10-PCS variant)
00HV0MZ	Surgical, central nervous system, insertion, spinal cord, neurostimulator lead, code by approach (ICD-10-PCS)
00HV3MZ	Surgical CNS insertion, spinal cord neurostimulator lead (ICD-10-PCS)
00HV4MZ	Surgical CNS insertion, spinal cord neurostimulator lead (ICD-10-PCS)
00WU0MZ	Surgical, central nervous system, removal, spinal canal, neurostimulator lead, code by approach (ICD-10-PCS)
00WU3MZ	Surgical CNS removal, spinal canal neurostimulator lead (ICD-10-PCS)
00WU4MZ	Surgical CNS removal, spinal canal neurostimulator lead (ICD-10-PCS)
00PV0MZ	Surgical, central nervous system, removal, spinal canal, neurostimulator lead, code by approach (ICD-10-PCS series)

1–10 of 17

1/2

ICD-10-PCS procedure codes appearing in this segmentICD-10

00PV3MZ	listed in code groups for neurostimulator procedures
00PV4MZ	listed in code groups for neurostimulator procedures
00WU0MZ	listed in code groups for neurostimulator procedures
00WU3MZ	listed in code groups for neurostimulator procedures
00WU4MZ	listed in code groups for neurostimulator procedures
00WV0MZ	listed in code groups for neurostimulator procedures
00WV3MZ	listed in code groups for neurostimulator procedures
00WV4MZ	listed in code groups for neurostimulator procedures
0JH60M6	Surgical, central nervous system, revision, spinal canal/spinal cord, neurostimulator lead, code by approach
0JH60M7	Surgical neurostimulator lead code variant

1–10 of 17

1/2

Referenced ICD-10-PCS codes (partial list group A)ICD-10

00WU3MZ	ICD-10-PCS code referenced for neurostimulator procedures (listed in document)
00WU4MZ	ICD-10-PCS code referenced for neurostimulator procedures (listed in document)
00WV0MZ	ICD-10-PCS code referenced for neurostimulator procedures (listed in document)
00WV3MZ	ICD-10-PCS code referenced for neurostimulator procedures (listed in document)
00WV4MZ	ICD-10-PCS code referenced for neurostimulator procedures (listed in document)

Referenced ICD-10-PCS codes (partial list group B)ICD-10

0JH60M6	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH60M7	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH60M8	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH60M9	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH63M6	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH63M7	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH63M8	ICD-10-PCS code referenced for neurostimulator lead/generator procedures
0JH63M9	ICD-10-PCS code referenced for neurostimulator lead/generator procedures

Referenced ICD-10-PCS codes (partial list group C)ICD-10

0JH70M6	ICD-10-PCS code referenced for stimulator generator insertion by body part/approach
0JH70M7	ICD-10-PCS code referenced for stimulator generator insertion by body part/approach
0JH70M8	ICD-10-PCS code referenced for stimulator generator insertion by body part/approach
0JH70M9	ICD-10-PCS code referenced for stimulator generator insertion by body part/approach
0JH73M6	ICD-10-PCS code referenced for stimulator generator insertion/revision
0JH73M7	ICD-10-PCS code referenced for stimulator generator insertion/revision
0JH73M8	ICD-10-PCS code referenced for stimulator generator insertion/revision
0JH73M9	ICD-10-PCS code referenced for stimulator generator insertion/revision

Listed ICD-10-PCS Procedure CodesICD-10-PCS

0JH60M6	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH60M7	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH60M8	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH60M9	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH63M6	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH63M7	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH63M8	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH63M9	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH70M6	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)
0JH70M7	Surgical, subcutaneous tissue and fascia, insertion, stimulator generator, specific body part/approach/arrays/rechargeable status (as listed)

1–10 of 23

1/3

Trial success thresholdneutral

>= 50% reduction in pain symptoms

Trial success threshold as defined for temporary stimulation trial

inv-45: Trial stimulation success threshold — ≥50% pain relief during trial period for eligibility for permanent implantation

Trial stimulation success threshold≥50% pain relief during the temporary trial period required to be eligible for permanent implantation

Typical trial durationTemporary trial typically lasts 3–7 days (site protocols reported 3–30 days in trials)

Documentation requirementRecord of patient-reported pain improvement during the trial (≥50%) must be included in clinical documentation

inv-46: Pain severity and duration (NICE) — ≥50 mm VAS and ≥6 months duration

Pain severity threshold (NICE)At least 50 mm on a 0–100 mm visual analog scale (VAS)

Duration requirement (NICE)Pain persisting for ≥6 months despite appropriate conventional medical management

Patient selection contextApplies to adults with chronic neuropathic-origin pain considered by a specialist team

inv-47: Parameters for complex programming — 4 or more parameters for complex programming (0789T)

Definition for complex programming (CPT 0789T)Electronic analysis with complex programming of an implanted integrated neurostimulation system when performed using 4 or more parameters

Example parameters includedContact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, detection algorithms, closed-loop parameters

Performed byPhysician or other qualified health care professional (as specified in coding descriptions)

inv-48: Programming parameter count — Simple programming: 1-3 parameters; Complex programming: 4 or more parameters

Simple programming1–3 parameters (electronic analysis with simple programming; e.g., 0788T/0785T context)

Complex programming4 or more parameters (electronic analysis with complex programming; CPT 0789T applies)

Parameters examplesIncludes contact group(s), amplitude, pulse width, frequency, on/off cycling, burst, and other device-specific settings

Imaging and Procedural Notes for Trial and Implantation

Note

Definitions and Key Terms

inv-110: Spinal Cord Stimulation (SCS) — definition key-value

DefinitionSpinal cord stimulation (SCS) — low-level epidural electrical stimulation of the spinal cord dorsal columns delivered via implanted leads, extension wire, and a power source to modulate pain signals

Device componentsLeads (4–8 electrodes), extension wire, and a power source (implantable battery or radiofrequency receiver)

Implantation processTypically a 2-step process: temporary epidural electrode trial followed by permanent implantation if trial demonstrates ≥50% pain reduction

inv-111: Dorsal Root Ganglion Stimulation (DRGS) — definition key-value

DefinitionDorsal root ganglion stimulation (DRGS) — neurostimulation targeting the dorsal root ganglion using an epidural approach to modulate sensory nerve cell bodies for focal neuropathic pain

Indications examplesUsed for localized chronic nerve pain such as complex regional pain syndrome, post-amputation pain, and other localized neuropathic conditions

Anatomic noteDRG are sensory cell bodies located in the epidural space on the posterior root and are amenable to epidural access for stimulation

inv-112: Burst stimulation — alternate programming mode definition

DefinitionBurst stimulation — an alternate programming mode delivered via a clinician programmer app that provides intermittent bursts (five 500‑Hz spikes at 40 Hz, pulse width ~1 ms) intended to reduce paresthesia

Delivery methodProvided as a clinician-programmer application supplement to standard SCS devices

PurposeProposed to relieve pain with fewer paresthesias compared with continuous tonic stimulation

inv-113: Treatment-refractory chronic trunk or limb pain — definition and examples

DefinitionTreatment-refractory chronic trunk or limb pain — chronic pain of the trunk or limbs that has failed conventional medical or surgical therapies

ExamplesIncludes failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), arachnoiditis, radiculopathies, phantom limb/stump pain, peripheral neuropathy, and painful diabetic neuropathy

Coverage contextSCS or DRGS considered when patients have failed other treatment modalities and documentation of prior therapies is provided

inv-114: Standard spinal cord stimulation (SCS) — definition

DefinitionStandard spinal cord stimulation (SCS) — epidural electrical stimulation of spinal cord dorsal columns using implanted leads (typically 4–8 electrodes), extension wire, and an implanted power source operating usually at 100–1000 Hz

Typical frequenciesStandard devices typically operate between 100 and 1000 Hz

Use caseSelected based on patient pain distribution; leads positioned at spinal cord level corresponding to pain pattern

inv-115: SCS — short label definition

Short labelSCS — Spinal cord stimulation

SynonymDorsal column stimulation

AbbrevSCS

inv-116: CMM — Conventional medical management definition

DefinitionCMM — Conventional medical management; noninvasive standard medical therapies used as comparators in trials

ContextOften includes medications, physical therapy, and other noninvasive treatments prior to considering SCS/DRGS

Role in trialsCMM is the comparator in many RCTs evaluating SCS interventions

inv-117: FBSS — Failed back surgery syndrome definition

DefinitionFBSS — Failed back surgery syndrome; persistent or recurrent pain following spinal surgery

Example contextListed among examples of treatment-refractory chronic trunk/limb pain

ImplicationMay be an indication considered for SCS when refractory to other therapies

inv-118: CRPS — Complex regional pain syndrome definition

DefinitionCRPS — Complex regional pain syndrome (also called reflex sympathetic dystrophy), a neuropathic pain condition often localized to a limb

Clinical noteIncluded as an example of treatment-refractory chronic pain in which SCS or DRGS may be considered

RelevanceDRGS has demonstrated efficacy for CRPS in trials

inv-119: High-frequency SCS — definition and example frequencies (10,000 Hz)

DefinitionHigh-frequency SCS — spinal cord stimulation delivered at higher frequencies (example: 10,000 Hz) intended to reduce paresthesias compared with standard SCS

Example frequency10,000 Hz cited as an example frequency for high-frequency devices

Trial evidence contextRCTs of high-frequency SCS used frequencies such as 5000 Hz and 10,000 Hz in trials

inv-120: IMMPACT core outcome domains — pain intensity, physical functioning, emotional functioning, participant ratings

Core IMMPACT domainsPain intensity; physical functioning; emotional functioning; participant ratings of overall improvement

UseRecommended for outcome measurement in clinical trials and documentation of SCS/DRGS effectiveness

BenchmarkingIMMPACT provides provisional benchmarks for clinically important changes in specific measures

inv-121: High-frequency SCS (trial definition) — delivered at high frequencies (examples 5000 Hz, 10,000 Hz)

Trial definition for high-frequency SCSHigh-frequency SCS trials delivered stimulation at high frequencies (examples include 5000 Hz and 10,000 Hz) and included a temporary trial stimulation period prior to permanent implantation

Example trialsPerruchoud et al (5000 Hz), Kapural et al and others (10,000 Hz) reported in RCTs

Population notesSome RCTs enrolled SCS-naive patients and required trial success for permanent implantation

inv-122: Responder — commonly defined as ≥50% reduction in pain from baseline

Responder definitionResponder commonly defined as ≥50% reduction in pain from baseline (e.g., VAS) in trial or follow-up assessments

Use in trialsMany RCTs and ACCURATE used ≥50% pain reduction as the threshold for successful trial and treatment success components

Documentation implicationResponder status should be documented in trial records to support permanent implantation decisions

inv-123: Dorsal root ganglion (DRG) — anatomical definition

Anatomic definitionDorsal root ganglion (DRG) — sensory cell bodies located in the epidural space between spinal nerves and the spinal cord on the posterior root

Physiologic roleTransmit peripheral sensory input to the central nervous system and can be targeted for neuropathic pain modulation via epidural access

Relevance to therapyDRG targeted stimulation allows more focal pain coverage with potentially less extraneous paresthesia

inv-124: Abbreviations — common abbreviations used in the policy

Common abbreviationsSCS: spinal cord stimulation; DRGS: dorsal root ganglion stimulation; VAS: visual analog scale; RCT: randomized controlled trial; IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

Additional abbreviationsCMM: conventional medical management; FBSS: failed back surgery syndrome; CRPS: complex regional pain syndrome; HFSCS: high-frequency spinal cord stimulation

UseAbbreviations used throughout policy and evidence summaries

inv-125: Temporary trial — definition and typical duration (3 to 30 days)

Temporary trial definitionShort-term implantation of stimulation (typically 3 to 30 days per trial protocols) to assess whether the patient achieves clinically significant pain reduction (e.g., ≥50% VAS reduction) before permanent implantation

Typical practiceMany device labels and trials use a temporary epidural electrode for the trial period prior to permanent implant

DocumentationTrial duration and pain response should be documented in clinical records for eligibility determination

inv-126: Critical limb ischemia — definition (context for indications)

DefinitionCritical limb ischemia — condition characterized by rest pain or ischemic limb lesions; considered in SCS evaluations when revascularization is not suitable

ContextSCS has been investigated for pain relief and potential limb-salvage in patients not suitable for revascularization; evidence is inconsistent

Coverage implicationNICE does not recommend routine SCS for ischemic origin pain except in research contexts

inv-127: Spinal cord stimulation (SCS) — restated definition

Definition (restated)Spinal cord stimulation (SCS) — low-level epidural electrical stimulation of spinal cord dorsal columns delivered via implanted leads, extension wire, and power source

ComponentsLead, extension, and power source; leads may have 4–8 electrodes and devices typically operate at 100–1000 Hz

Clinical pathwayTrial stimulation followed by permanent implantation if trial demonstrates adequate pain relief

inv-128: Trial period — temporary implantation to assess response prior to permanent implantation

Trial periodTemporary implantation of electrode in the epidural space to assess response prior to permanent implantation

PurposeAllows assessment of pain relief and tolerability of stimulation before committing to a permanent implant

Typical documentationRecord of trial duration, pain scores, and responder status (e.g., ≥50% reduction) required

inv-129: Treatment-refractory chronic pain — definition for policy context

DefinitionTreatment-refractory chronic pain — chronic trunk or limb pain that has failed standard/conventional therapies and for which SCS/DRGS may be considered

Evidence noteTrials showing benefit often enrolled patients with neuropathic pain processes and prior failed therapies

Documentation expectationProviders should document prior treatments tried and unsatisfactory responses

inv-130: Successful trial of stimulation — temporary electrode demonstration of pain relief prior to permanent implantation

DefinitionSuccessful trial of stimulation — temporary implanted electrode demonstration of clinically significant pain relief (commonly ≥50%) prior to permanent implantation

Role in trialsPatients who failed temporary trial were considered treatment failures and did not proceed to permanent implantation in RCTs

DocumentationSuccessful trial and absence of stimulation-related neurologic deficits should be recorded

inv-131: NICE candidate criteria — Adults with chronic neuropathic-origin pain >=50 mm VAS and >=6 months duration

NICE candidate criteriaAdults with chronic neuropathic-origin pain measuring at least 50 mm on 0–100 mm VAS, persisting ≥6 months despite appropriate conventional management, and who have had a successful trial of stimulation assessed by a specialist team

Assessment teamSpecialist team assessment required as part of candidate selection

Research noteNICE does not recommend SCS for ischemic-origin chronic pain except in research settings

inv-132: Evidence-based consensus guidelines — references to society guidelines for selection and trial stimulation

Guideline referencesEvidence-based consensus guidelines and society guidance (e.g., ASRA‑PM, ASIPP, ASPN, NEURON group) inform patient selection and trial stimulation practices

ApplicationGuidelines recommend trial stimulation before definitive implant (except select indications) and psychosocial screening prior to implantation

Use in prior authPrior authorization processes should consider guideline-recommended requirements for trial and multidisciplinary evaluation

inv-133: Electronic analysis/programming — simple vs complex programming definitions

DefinitionElectronic analysis/programming — device interrogation and programming categorized as simple (1–3 parameters) or complex (≥4 parameters) electronic analysis of an implanted integrated neurostimulation system

Examples of parametersContact groups, amplitude, pulse width, frequency, on/off cycling, burst, detection algorithms, closed-loop parameters

Relevant CPT/HCPCSAssociated codes include 95970/95971 (analysis), 95972 (simple programming), 0788T/0789T (integrated system programming) as described in coding section

inv-134: Neurostimulator generator insertion — ICD-10-PCS descriptor reference

DefinitionNeurostimulator generator insertion — surgical insertion of stimulator generator (subcutaneous tissue and fascia) coded by body part, approach, number of arrays, and rechargeable status (ICD-10-PCS descriptors)

Coding noteICD-10-PCS codes (e.g., 0JH60M6 and variants) used to specify approach and device characteristics for generator insertion

DocumentationProcedure documentation must support chosen code including body part, approach, arrays, and rechargeable status

inv-135: Neurostimulator lead revision — ICD-10-PCS descriptor reference

DefinitionNeurostimulator lead revision — surgical revision or replacement of spinal neurostimulator lead(s), coded by approach (ICD-10-PCS descriptors)

Common CPT referencesCPT codes for lead removal/revision include 63661–63664 as listed in coding section

DocumentationRecord approach, number of arrays, and reason for revision to support coding and authorization

inv-136: Refractory to other pain therapies — definition node (also listed under conservative requirements)

DefinitionRefractory to other pain therapies — patient has failed appropriate medical and/or surgical therapies prior to consideration of SCS/DRGS

Trial evidenceRCTs generally required prior conservative therapy attempts before enrollment

Documentation expectationProviders should document prior therapies attempted and unsatisfactory responses

Frequency and Trial-to-Implant Limits

inv-148: Temporary SCS trial followed by permanent implant only if trial successful

RequirementTemporary SCS trial must be performed and permanent implant only if trial is successful (trial success commonly defined as ≥50% pain reduction)

Trial documentationPrior authorization and clinical records should include trial period details and responder status

Exception noteSome guideline statements allow exceptions (e.g., anginal pain) where trial may not be required

inv-149: SCS implantation and revisions: no explicit numeric frequency limits provided in this excerpt

StatementSCS implantation and device revision/removal CPTs and ICD-10-PCS codes are listed for billing and prior authorization reference

Frequency limits noteNo explicit numeric frequency limits for implantation or revisions are provided in the cited excerpts

Coding implicationInclusion of procedure codes does not guarantee coverage; documentation must support medical necessity

inv-150: Trial implantation followed by potential permanent implantation

Procedure pathwayTrial implantation with temporary epidural electrode is performed first; if trial is successful, patient may proceed to permanent implantation

Trial durationTemporary trial durations reported in trials range from 3 to 30 days depending on site protocol

DocumentationClinical records should document trial conduct, duration, and response to support permanent implant decision

inv-151: Dorsal root ganglion neurostimulation — listed as distinct therapy (frequency limits not specified)

ClassificationDorsal root ganglion neurostimulation is listed as a distinct therapy targeting the DRG via epidural approach and intended for localized neuropathic pain

Coding/frequency noteFrequency limits for DRGS-specific procedures are not specified in the cited chunks

Coverage contextDRGS considered for treatment-refractory chronic trunk/limb neuropathic pain when performed per guidelines and trial success

inv-152: Removal, revision, implantation CPTs listed but no explicit frequency limits in these chunks

Codes listedProcedure and device CPT/HCPCS and ICD-10-PCS codes for removal, revision, and implantation are provided in the coding sections

Frequency limitsNo explicit frequency limits for these CPTs are provided in the cited document excerpts

Prior authorization implicationPrior authorization applies to listed implantation codes and must reflect specific procedure details

Background and Evidence Context

Background: Spinal cord stimulation (SCS) delivers low‑level epidural electrical stimulation to the dorsal columns of the spinal cord via implanted leads and a power source to modulate pain signaling. Dorsal root ganglion stimulation (DRGS) targets the dorsal root ganglion for more focal neuromodulation of localized neuropathic pain. Both are neuromodulation techniques intended for patients with chronic, treatment‑refractory pain and are typically trialed with a temporary epidural lead prior to permanent implantation.

Not Covered / Investigational Indications

Not covered: The policy explicitly lists treatment of critical limb ischemia to forestall amputation, refractory angina pectoris, and heart failure among indications considered investigational or not covered; these conditions lack sufficient high‑quality RCT evidence to support routine SCS use.